A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage

被引：0
|
作者：
Zhou, Jian
Fan, Jia
Gu, Fang-Ming
Li, Tao
Bai, Dou-Sheng
Sun, Hui-Chuan
Wang, Zheng
Qiu, Shuang-Jian
Ye, Qing-Hai
Shi, Ying-Hong
Gao, Qiang
Wang, Xiao-Ying
Yang, Xin-Rong
Shi, Guo-Ming
Peng, Yuan-Fei
机构：
[1] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Minist Educ, Shanghai, Peoples R China
[2] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Shanghai, Peoples R China
[3] Naval Med Univ, Affiliated Hosp 3, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China
[4] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[5] Yangzhou Univ, Subei Peoples Hosp, Yangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4126
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.
    Xia, Yongxiang
    Wang, Ping
    Pu, Liyong
    Qian, Xiaofeng
    Cheng, Feng
    Wang, Ke
    Zhang, Chuanyong
    Li, Donghua
    Li, Xiangcheng
    Zhang, Feng
    Zhao, Jie
    Li, Si
    Xi, Wenjing
    Wang, Xuehao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study
    Cui, Yunlong
    Bao, Xu
    Yu, Ge
    Li, Huikai
    Fang, Feng
    Li, Qiang
    Zhang, Wei
    Wu, Qiang
    Chen, Lu
    Liu, Chen
    Song, Tianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
    Xia, Yongxiang
    Tang, Weiwei
    Qian, Xiaofeng
    Li, Xiangcheng
    Cheng, Feng
    Wang, Ke
    Zhang, Feng
    Zhang, Chuanyong
    Li, Donghua
    Song, Jinhua
    Zhang, Hui
    Zhao, Jie
    Yao, Aihua
    Wu, Xiaofeng
    Wu, Chen
    Ji, Guwei
    Liu, Xisheng
    Zhu, Feipeng
    Qin, Lang
    Xiao, Xuan
    Deng, Zhenhua
    Kong, Xiangyi
    Li, Si
    Yu, Yangyang
    Xi, Wenjing
    Deng, Wanglong
    Qi, Chuang
    Liu, Hanyuan
    Pu, Liyong
    Wang, Ping
    Wang, Xuehao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [4] A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.
    Song, Tianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial
    Yang, X.
    Sun, H.
    Hu, B.
    Wu, S-Y.
    Shi, Y-H.
    Wang, X-Y.
    Gao, Q.
    Huang, C.
    Wang, Z.
    Shi, G-M.
    He, Y-F.
    Ding, Z-B.
    Peng, Y-F.
    Sun, J.
    Huang, X-W.
    Ye, Q-H.
    Qiu, S-J.
    Zhou, J.
    Fan, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S824 - S824
  • [6] Updated results from venous infusion chemotherapy (VIC) plus apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
    Peng, Linhui
    Chen, Tao
    Chen, Yajin
    Xu, Yunxiuxiu
    Wang, Jie
    Chen, Jie
    Li, Yong
    Huang, Pinbo
    Hu, Xiao
    Zhong, Guoping
    Chen, Xi
    Ye, Congting
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Chemoradiation with raltitrexed in preoperative treatment of stage II/III resectable rectal cancer: long term results of a phase II study
    Gambacorta, M. A.
    Valentini, V.
    Giammarino, D.
    Balducci, M.
    Ciresa, M.
    Montoro, C.
    Marazzi, F.
    Pacelli, F.
    Ratto, C.
    Doglietto, G. B.
    EJC SUPPLEMENTS, 2005, 3 (02): : 193 - 193
  • [8] Borderline resectable hepatocellular carcinoma: Definitions, efficacy and safety results from a prospective phase Ib/II study evaluating camrelizumab plus lenvatinib combined with TACE as preoperative therapy (BRHCC)
    Liao, M.
    Yang, Y.
    Jiang, H.
    Huang, J.
    Liu, C.
    Yang, Y.
    Xie, K.
    Luo, X.
    Zhou, J.
    Wang, X.
    Wu, H.
    Zeng, Y.
    Li, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S664 - S665
  • [9] Venous infusion chemotherapy (VIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in CNLC stage III: A prospective, single-arm, phase II trial.
    Peng, Linhui
    Chen, Tao
    Chen, Yajin
    Xu Yunxiuxiu
    Wang, Jie
    Zhong, Guoping
    Xiao, Zhiyu
    Zhou, Zhenyu
    Ye, Congting
    Li, Yong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Oxaliplatin-based Chemoradiation Schema for Stage II and III Rectal Carcinoma; Results from a Phase II Study
    Young, R.
    Kozuch, P. S.
    Enker, W.
    Martz, J.
    Bernstein, M.
    Evans, A.
    Malamud, S.
    Rische, E.
    Kumar, M.
    Hu, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S264 - S265
12345